Onsdag 29 April | 21:06:26 Europe / Stockholm

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-04-29 15:23:00

Circio Holding ASA ("Circio" or "the Company") announced, on the 29th of April 2026, a research collaboration with Universidad de Santiago de Compostela ("USC"), through USC's TraffikGene project, to evaluate non-viral delivery of circVec using TraffikGene's proprietary peptide amphiphile carrier system. The aim is to assess whether the TraffikGene technology can deliver circVec into novel tissues for gene and cell therapy applications. The collaboration will proceed in three stages: in vitro screening of peptide carriers, physicochemical optimization of lead formulations, and in vivo evaluation in mouse models. TraffikGene is led by Prof. Javier Montenegro at CiQUS and is currently being spun out into an independent company. No financial terms were disclosed.

In summary, Analyst Group views the TraffikGene collaboration as a strategically coherent extension of Circio's delivery partnership network that reinforces the delivery-agnostic positioning of circVec and broadens its potential reach beyond immune-cell applications. That said, the collaboration remains at a preclinical technical-feasibility stage with no disclosed financial terms, and the principal near-term value drivers continue to be the in vivo CAR-T data package expected during Q3/Q4-26, the disease-model efficacy readouts in eye and heart in Q4-26, and the partnered project update from the big pharma CNS feasibility study in Q4-26.


Read Analyst Group’s comment here


About Analyst Group: One of Sweden's leading equity research boutiques with focus on small and medium-sized listed companies.
Read more about Analyst Group
 
This is a press release from Analyst Group regarding the publication of a comment on Circio Holding. Readers may assume that Analyst Group has received compensation for making the comment. The Company has not been given an opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation or anything else that could be considered a subjective assessment.